Katy Wong, Ph.D.

PROFILE

- Strong background in oncology, 15+yrs experience
  - Supported four drug launches, >10 clinical trials, 11 investigator initiated trials
  - Research experience in MAPK signaling, GBM, and NSCLC
  - Diagnostics Lead: Trained internal stakeholders and developed field resources in the area of circulating tumor DNA and molecular testing.
- Highly motivated, fast learner with strong oral and written communication skills.
  - AstraZeneca Rookie of the Year, chosen from MSLs across all therapeutics areas
- Able to multi-task and juggle independent and team projects.
  - Covers West territory, Kaiser Medical Affairs lead
- Strong presentation skills resulting in the Young Investigators Award and Albert and Doris Woeltjen Poster Award.

EDUCATION

University of Illinois at Chicago, Doctoral Advisor: John P. O'Bryan, Ph.D. **Chicago, IL**
Ph.D. in Pharmacology *June 2012*
Dissertation: Intersectin: A Regulator of Cell Signaling

California Polytechnic State University **San Luis Obispo, CA**
B.S. in Biochemistry *June 2005*

EXPERIENCE

Foundation Medicine **Cambridge, MA**
Senior Medical Science Liaison-Oncology *Sept 2019-Present*

- Supports diagnostic portfolio: FoundationOne CDx, FoundationLiquid CDx and FoundationHeme.
- Provides genomic testing education across all solid tumors and hematological malignancies.

AstraZeneca **Gaithersburg, MD**
Senior Medical Science Liaison-Oncology *March 2015-Sept 2019*

- Supported four drug launches and >10 clinical trials (Phase I-III).
- Established relationships with external experts collected insights, recruited for advisory boards, speaking engagements, and study participation.
- Coordinated internal and external activities to support review and approval of 11 externally sponsored research proposals.
- Collaborated with cross-functional team members to drive awareness of oncology pipeline.
- Diagnostics Lead
  - Trained internal stakeholders and developed field resources in the area of circulating tumor DNA and molecular testing.
- Veterans Association Lead
  - Worked with VA on a national level and established relationship to open clinical trials.
- Facilitated communication between healthcare professionals and AstraZeneca.
  - Collected insights on medical trends, competitors, and healthcare landscape.
- Educated the medical community on AstraZeneca ongoing research, scientific issues, and disease state.

Tufts Medical Center **Boston, MA**
Postdoctoral Fellow, Molecular Oncology Research Institute *June 2012 – March 2015*

- Generated a mouse model for ROS1 fusion kinase driven NSCLC to mimic clinically relevant mutations and treatment. Used these models to predict patient treatment and resistance.
- Used patient data gathered by The Cancer Genome Atlas to identify relevant mouse models for GBM, including EGFR, EGFRvIII, PTEN null, and Cdkn2a null tumors.
- Identified novel exosome GBM biomarkers to track tumor growth over time and during therapeutic intervention, (i.e. gefitinib, ionizing radiation, temozolomide) resulting in Young Investigators Award.

University of Illinois at Chicago **Chicago, IL**
Ph.D. Candidate *Aug. 2005 – May 2012*

- Discovered a novel PI3K-Ras signaling pathway resulting in three first author publications.
  - Performed in vitro kinase assays to show nucleotide-free Ras directly interacts with and inhibits PI3K to reduce cellular transformation.
  - Used bimolecular fluorescence complementation to show that nucleotide-free Ras is a novel effector of PI3K.
  - Used transfection and protein detection to demonstrate that the activation of AKT by scaffold protein, intersectin, is dependent on Ras and PI3K.
- Supervised and trained graduate students, as well the hiring, training, and management of two undergraduate research assistants

PUBLICATIONS

Zou, H.Y., Qiuhua, L., Engstrom, L.D., Lu, M.W., Appleman, V, **Wong, K.A.**, McTigue, M., Deng,Y-L, Liu, W., Brooun, A., Timofeevski, S., McDonnell, S., Jiang, P., Falk, M.D., Lappin, P.B., Affolter, T., Nicholes, T., Hu, W., Lam, J., Johnson, T.W., Smeal, T., Charest, A., Fantin, V.R., PF-06463922, a potent and selective next generation ROS1/ALK inhibitor capable of blocking crizotinib resistant ROS1 mutations. (2015) PNAS, Mar 17; 112 (11): 3493-8

Wong, K.A., Wang, X., Chen, Y.-J., Lavie, A., O'Bryan, J.P., A New Dimension to Ras Function: A Novel Role for Nucleotide-Free Ras in Class II Phosphatidylinositol 3-Kinase Beta (PI3K-beta) Regulation. (2012) PLoS ONE 7(9):e45360

Wong, K.A., Wilson, J., Russo, A., Wang L., Okur, M.N., Wang, X.,Martin, N.P., Scappini, E., Carnegie, G., O'Bryan, J.P., Intersectin (ITSN) family of scaffolds function as a molecular hubs in protein interaction networks. (2012) PLoS ONE 7(4):e36023

Wong, K.A., O'Bryan J.P., Bimolecular fluorescence complementation. (2010) Journal of Visualized Experiments. DOI 10.3791/2643

Das, M., Scappini, E., Martin, N.P., **Wong K.A.**, Dunn, S., Chen, Y., Domin, J., O'Bryan, J.P. Regulation of Neuron Survival Through an Intersectin-Phosphoinositide 3'-Kinase C2□-AKT Pathway. (2007) Mol Cell Biol 27, 7906

HONORS AND ORAL PRESENTATIONS

International Society for Extracellular Vesicles **Boston, MA**
Young Investigator Award *April 2013*

University of Illinois at Chicago, Department of Pharmacology **Chicago, IL**
Albert and Doris Woeltjen Poster Award (2nd place) *Oct. 2009, Oct. 2010*

University of Illinois at Chicago **Chicago, IL**
Graduate College Travel Award *April 2008, May 2009, Aug. 2010*

Cold Spring Harbor: Phosphorylation, Signaling and Disease **Cold Spring Harbor, NY**
Ras regulates PIK through a novel mechanism, invited speaker *May 2009*

University of Illinois at Chicago, Department of Pharmacology **Chicago, IL**
Seminar: The Role of Intersectin in a Ras-Phosphoinositide 3'-Kinase- AKT Pathway *Oct. 2009*

University of Illinois at Chicago Department of Pharmacology Seminar **Chicago, IL**
Seminar: Intersectin's Connection to the Rab Trafficking Pathway *Feb. 2008*